Remove Healthcare Remove Pharmaceutical manufacturing Remove Physicians Remove Safety
article thumbnail

Leading patient adherence pharmaceutical companies

Pharmaceutical Technology

Pharmaceutical and healthcare companies are working continuously to improve patient adherence, which also impacts disease control and pharmaceutical industry revenues directly. Pharmaceutical companies are increasingly integrating data-driven and software-centric medical adherence products to improve patient compliance.

Leads 52
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Among the 25 worldwide companies that spend the most on research and development—all more than $5 billion a year—seven are pharmaceutical manufacturers, but eight are automobile or automobile parts companies with profit margins under 10 percent. It also raises healthcare costs for public and private insurers alike.

Pharma 255
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. andrew.mills@caretrack.com CareTrack Health is a fully integrated physician practice extension. Furthermore, it is estimated to reach $6.5 Andrew Mills.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

For example, the US recently passed the Inflation Reduction Act, 1 which requires the Secretary of Health and Human Services (HHS) to negotiate prices for certain physician-administered and retail prescription drugs covered under Medicare Parts B and D.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We This design will enable physicians to take more informed and robust treatment decisions than in most other cases,” Chiesi said. But rare diseases are a particularly important and challenging focus area.